Comparative Pharmacology
Head-to-head clinical analysis: CYCLACILLIN versus LANABIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLACILLIN versus LANABIOTIC.
CYCLACILLIN vs LANABIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
LANABIOTIC is a lantibiotic that inhibits bacterial cell wall synthesis by binding to lipid II, a key precursor in peptidoglycan biosynthesis, thereby disrupting cell wall integrity and causing cell death.
250-500 mg orally every 6 hours.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
Clinical Note
moderateCyclacillin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."
Clinical Note
moderateCyclacillin + Mycophenolic acid
"The serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy."
Clinical Note
moderateCyclacillin + Plicamycin
"The serum concentration of Plicamycin can be decreased when it is combined with Cyclacillin."
Clinical Note
moderateTerminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-30%.
Category C
Category C
Antibiotic
Antibiotic
Cyclacillin + Valrubicin
"The serum concentration of Valrubicin can be decreased when it is combined with Cyclacillin."